Cargando…
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4
Autores principales: | Ishida, Yuriko, Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Ogura, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835993/ https://www.ncbi.nlm.nih.gov/pubmed/36655228 http://dx.doi.org/10.1183/23120541.00337-2022 |
Ejemplares similares
-
Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
por: Funke-Chambour, Manuela, et al.
Publicado: (2022) -
Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
por: Ikeda, Satoshi, et al.
Publicado: (2021) -
Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer
por: Okabayashi, Hiroko, et al.
Publicado: (2021) -
Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis
por: Yamakawa, Hideaki, et al.
Publicado: (2016) -
A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap Syndrome
por: Yamakawa, Hideaki, et al.
Publicado: (2017)